Genentech, Inc., Oncology Biomarker Development, 1 DNA Way, South San Francisco, 94080-4990, USA.
Expert Opin Biol Ther. 2010 Sep;10(9):1343-55. doi: 10.1517/14712598.2010.512003.
Heterodimerization of human EGF receptor (HER) 2 and HER3, a co-receptor of HER2, plays an important and dominant role in the functionality and transformation of HER-mediated pathways. Understanding the role of HER3 in oncogenesis as well as its place as a target for anticancer therapy is an ongoing area of research. Determination of biomarkers for clinical benefit from agents targeting HER3 is an essential component of translating basic science into real-world effective anticancer therapies, with the aim of ensuring the patients most likely to benefit from such treatments can be identified.
This review focuses on the targeting of HER2 and HER3 by monoclonal antibodies and the potential for HER3 mRNA levels to predict treatment outcome in ovarian cancer.
An understanding of the value of biomarkers for clinical benefit to anticancer therapy and the current status of HER3 mRNA as a biomarker for clinical benefit of the HER2-HER3 dimerization inhibitor pertuzumab.
HER3 mRNA levels may be a biomarker for active ligand-induced HER2-HER3 signaling, with low HER3 mRNA levels correlated with clinical benefit from the HER2-HER3 dimerization inhibitor pertuzumab.
人表皮生长因子受体（HER）2 和 HER3 的异二聚化，HER2 的共受体，在 HER 介导的途径的功能和转化中发挥着重要和主导作用。了解 HER3 在肿瘤发生中的作用及其作为抗癌治疗靶点的地位是正在进行的研究领域。确定针对 HER3 的靶向药物的生物标志物对于将基础科学转化为现实世界的有效抗癌疗法至关重要，目的是确保能够识别最有可能从这些治疗中受益的患者。
本综述重点介绍了单克隆抗体对 HER2 和 HER3 的靶向作用，以及 HER3 mRNA 水平在预测卵巢癌治疗结果方面的潜力。
对生物标志物对癌症治疗临床获益的价值的理解，以及目前作为 HER2-HER3 二聚化抑制剂 pertuzumab 临床获益的生物标志物的 HER3 mRNA 的现状。
HER3 mRNA 水平可能是活性配体诱导的 HER2-HER3 信号的生物标志物，低 HER3 mRNA 水平与 HER2-HER3 二聚化抑制剂 pertuzumab 的临床获益相关。
